Pfizer to launch 3 biosimilars

Pfizer is set to introduce three new biosimilars this year. The company said it plans to launch Avastin biosimilar Zirabev (bevacizumab-bvzr); Rituxan biosimilar Ruxience (rituximab-pvvr); and Herceptin biosimilar Trazimera (trastuzumab-qyyp).

The medicines are expected to launch at the lowest wholesale acquisition cost among all other bevacizumab, rituximab or trastuzumab products currently on the market, becoming available at a substantially discounted price to the originator product, the company said.

Zirabev is indicated for the treatment of five types of cancer: metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous, non-small cell lung cancer; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent or metastatic cervical cancer.

Ruxience is available for the treatment of adult patients with non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and granulomatosis with polyangiitis and microscopic polyangiitis.

Trazimera is indicated for the treatment of human epidermal growth factor receptor 2 overexpressing breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.

“We’re proud to expand our leading biosimilars portfolio by launching these three treatments, which can potentially create significant savings for the U.S. healthcare system while increasing access to critical therapies,” said Angela Lukin, Pfizer regional president, North America oncology. “We look forward to working with payers and providers to deliver these important medicines to patients that are living with certain cancers and autoimmune conditions.”